Ligand Pharmaceuticals Incorporated (LGND)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 1.24B |
| Enterprise value | 1.07B |
| Trailing P/E | 23.07 |
| Forward P/E | 26.11 |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 9.45 |
| Price/book (mrq) | 1.77 |
| Enterprise value/revenue | 8.17 |
| Enterprise value/EBITDA | 10.74 |
Trading information
Stock price history
| Beta (5Y monthly) | 0.92 |
| 52-week change 3 | -9.90% |
| S&P500 52-week change 3 | 25.01% |
| 52-week high 3 | 94.57 |
| 52-week low 3 | 49.24 |
| 50-day moving average 3 | 74.93 |
| 200-day moving average 3 | 66.91 |
Share statistics
| Avg vol (3-month) 3 | 173.44k |
| Avg vol (10-day) 3 | 163.5k |
| Shares outstanding 5 | 17.71M |
| Implied shares outstanding 6 | 17.71M |
| Float 8 | 16.67M |
| % held by insiders 1 | 5.93% |
| % held by institutions 1 | 94.45% |
| Shares short (28 Mar 2024) 4 | 672.08k |
| Short ratio (28 Mar 2024) 4 | 3.1 |
| Short % of float (28 Mar 2024) 4 | 5.54% |
| Short % of shares outstanding (28 Mar 2024) 4 | 3.80% |
| Shares short (prior month 29 Feb 2024) 4 | 762.64k |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | 02 Jul 2010 |
| Last split factor 2 | 1603:1000 |
| Last split date 3 | 02 Nov 2022 |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | 39.72% |
| Operating margin (ttm) | -11.95% |
Management effectiveness
| Return on assets (ttm) | 0.79% |
| Return on equity (ttm) | 8.29% |
Income statement
| Revenue (ttm) | 131.31M |
| Revenue per share (ttm) | 7.59 |
| Quarterly revenue growth (yoy) | -44.20% |
| Gross profit (ttm) | N/A |
| EBITDA | 45.46M |
| Net income avi to common (ttm) | 53.82M |
| Diluted EPS (ttm) | 3.03 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 170.31M |
| Total cash per share (mrq) | 9.62 |
| Total debt (mrq) | 6.18M |
| Total debt/equity (mrq) | 0.88% |
| Current ratio (mrq) | 14.15 |
| Book value per share (mrq) | 39.92 |
Cash flow statement
| Operating cash flow (ttm) | 49.58M |
| Levered free cash flow (ttm) | -4.76M |
© 2024 Yahoo. All rights reserved.